Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy

Diabetes Care

Volumn 26, Issue 6, 2003, Pages 1889-1894

  Kusunoki, Hitomi ^a   Miyata, Satoshi ^a   Ohara, Takeshi ^a,b   Liu, Bing Fen ^a   Uriuhara, Atsuko ^a   Kojima, Hiroshi ^a   Suzuki, Kotaro ^a   Miyazaki, Hiroyuki ^a   Yamashita, Yumiko ^a   Inaba, Kayo ^a   Kasuga, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Japan   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; HEMOGLOBIN A1C;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; SERUM;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYGLUCOSE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FASTING; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; PLATELET ACTIVATING FACTOR; REFERENCE VALUES;

EID: 10744219748     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.6.1889     Document Type: Article

References (39)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 329:977-986, 1993
2. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
4. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314:403-408, 1986
5. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissues and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
6. Miyata S, Monnier VM: Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 89:1102-1112, 1992
7. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9, 1999
8. Shamsi FA, Partal A, Sady C, Glomb MA, Nagaraj RH: Immunological evidence for methylglyoxal-derived modifications in vivo: determination of antigenic epitopes. J Biol Chem 273:6928-6936, 1998
9. Horie H, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, Strihou CY, Monnier VM, Witzum JL, Kurokawa K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100:2995-3004, 1997
10. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40:764-769, 1997
11. ε-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 40: 1380-1387, 1997
12. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 48:517-526, 1995
13. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, Uchida K: Methylglyoxal modification of protein: chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 274:18492-18502, 1999
14. Takahashi M, Lu YB, Myint T, Fujii J, Wada Y, Taniguchi N: In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. Biochemistry 34:1433-1438, 1995
15. Miyata S, Liu B-F, Shoda H, Ohara T, Yamada H, Suzuki K, Kasuga M: Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. J Biol Chem 272: 4037-4042, 1997
16. Vlassara H, Brownlee M, Manogue KR, Dinarello C, Pasagian A: Cachectin/TNF and IL-1-induced by glucose modified proteins: role in normal tissue remodeling. Science 240:1546-1548, 1988
17. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 96:1395-1403, 1995
18. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001
19. Kato H: Chemical studies on aminodicarbonyl reaction. Part 1: isolation of 3-deoxyglucosone and 3-deoxyhexosones formed by browning degradation of N-glycosides. Agr Biol Chem 26:187-192, 1962
20. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM: Aging of proteins: immunological detection of glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 264:3758-3764, 1989
21. Konishi Y, Hayase F, Kato H: Novel imidazolone compound formed by the advanced Maillard reaction of 3-deoxyglucosone and arginine residues in proteins. Biosci Biotechnol Biochem 58:1953-1955, 1994
22. Thomalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116, 1999
23. Shin DB, Hayase F, Kato H: Polymerization of proteins caused by reaction with sugars and the formation of 3-deoxyglucosone under physiological conditions. Agric Biol Chem 52:1451-1458, 1988
24. Szwergold BS, Kappler F, Brown TR: Identification of fructose 3-phosphate in the lens of diabetic rats. Science 247:451-454, 1990
25. Shinoda T, Hayase F, Kato H: Suppression of cell-cycle progression during the S phase of rat fibroblasts by 3-deoxyglucosone, a Maillard reaction intermediate. Biosci Biotechnol Biochem 58:2215-2219, 1994
26. Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J, Taniguchi N: Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun 225:219-224, 1996
27. Che W, Asahi M, Takahashi M, Kaneto H, Okado A, Higashiyama S, Taniguchi N: Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells. J Biol Chem 272:18453-18459, 1997
28. Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M: Increase in 3-deoxyglucosone levels in diabetic rat plasma. J Biol Chem 269:20275-20280, 1994
29. Knecht KJ, Feather MS, Baynes JW: Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. Arch Biochem Biophys 294:130-137, 1992
30. Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Ohara M, Tomiyama S, Niimura K: Presence of 3-deoxyglucosone, a potent protein crosslinking intermediate of Maillard reaction, in diabetic serum. Biochem Biophys Res Commun 196:837-843, 1993
31. Lal S, Kappler F, Walker M, Orchard TJ, Beisswenger PJ, Szwergold BS, Brown TR: Quantitation of 3-deoxyglucosone levels in human plasma. Arch Biochem Biophys 342:254-260, 1997
32. Hamada Y, Nakamura J, Fujisawa H, Yago H, Nakashima E, Koh N, Hotta N: Effect of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care 20:1466-1469, 1997
33. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
34. Kato H, Shin DB, Hayase F: 3-Deoxyglucosone crosslinks proteins under physiological conditions. Agric Biol Chem 51: 2009-2011, 1987
35. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99: 1272-1280, 1997
36. ε(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23: 1539-1544, 2000
37. Kanazu T, Shinoda M, Nakayama T, Deyashiki Y, Hara A, Sawada H: Aldehyde reductase is a major 3-deoxyglucosone reductase activity in rat, pig and human livers. Biochem J 279:903-906, 1991
38. Kato H, van-Chuyen N, Shinoda T, Sekiya F, Hayase F: Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1035:71-76, 1990
39. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS: α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732, 2001